# AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

> **NCT07021950** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 130 (estimated)

## Conditions studied

- Colorectal Cancer
- Ivonescimab

## Interventions

- **DRUG:** AK112
- **DRUG:** FOLFIRI
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07021950
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-10
- **Primary completion:** 2027-10-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07021950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07021950, "AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07021950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*